{"entity":{"id":"nct07288879","kind":"trial","name":"DALY II Japan/MB-CART2019.1 for DLBCL","aka":[],"tldr":"A phase 2 trial of Zamtocabtagene autoleucel in diffuse large b-cell lymphoma, run by Miltenyi Biomedicine GmbH, now recruiting.","summary":"DALY II Japan/MB-CART2019.1 for DLBCL is a phase 2 interventional study registered as NCT07288879 by Miltenyi Biomedicine GmbH, with 31 participants planned, started 2025-12-11 and due to reach its primary completion in 2027-01-31. Interventions recorded: MB-CART2019.1. Conditions listed: DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07288879","url":"https://clinicaltrials.gov/study/NCT07288879"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["zamtocabtagene-autoleucel"],"companies":["miltenyi-biomedicine"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07288879","phase":"2","setting":"A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma.","sponsor":"Miltenyi Biomedicine GmbH","enrolled":31,"outcomes":[]},"route":"/trials/nct07288879/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","route":"/drugs/zamtocabtagene-autoleucel/"}],"company":[{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/"}]}}